Unknown

Dataset Information

0

Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).


ABSTRACT: Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1st, 2nd, and 3rd line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC; hence, it is considered a promising therapeutic target. Areas covered: We comprehensively reviewed the evidence from preclinical and phase I and II clinical trials, based on the authors'clinical experience and a PubMed, Cochrane library, Embase, and Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination with stroma-targeted therapies may be a promising area to explore in clinical trials.

SUBMITTER: Babiker HM 

PROVIDER: S-EPMC6681663 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5078653 | BioStudies
2017-01-01 | S-EPMC5330615 | BioStudies
2015-01-01 | S-EPMC4571987 | BioStudies
2020-01-01 | S-EPMC6965047 | BioStudies
1000-01-01 | S-EPMC5129993 | BioStudies
2017-01-01 | S-EPMC5349426 | BioStudies
2020-01-01 | S-EPMC7464161 | BioStudies
2017-01-01 | S-EPMC5238457 | BioStudies
1000-01-01 | S-EPMC4769991 | BioStudies
1000-01-01 | S-EPMC4464647 | BioStudies